T Cells in Systemic Lupus Erythematosus

Rheum Dis Clin North Am. 2021 Aug;47(3):379-393. doi: 10.1016/j.rdc.2021.04.005. Epub 2021 Jun 16.

Abstract

T-cell dysregulation has been implicated in the loss of tolerance and overactivation of B cells in systemic lupus erythematosus (SLE). Recent studies have identified T-cell subsets and genetic, epigenetic, and environmental factors that contribute to pathogenic T-cell differentiation, as well as disease pathogenesis and clinical phenotypes in SLE. Many therapeutics targeting T-cell pathways are under development, and although many have not progressed in clinical trials, the recent approval of the calcineurin inhibitor voclosporin is encouraging. Further study of T-cell subsets and biomarkers of T-cell action may pave the way for specific targeting of pathogenic T-cell populations in SLE.

Keywords: Cytokines; Epigenetics; Lupus; Metabolism; Systemic lupus erythematosus; T cells; T-cell subsets.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • B-Lymphocytes
  • Humans
  • Lupus Erythematosus, Systemic* / drug therapy
  • T-Lymphocytes*